Integrin alpha 3/CD49c RNAi Summary
Specificity |
integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) (ITGA3), transcript variant a, mRNA
|
Gene |
ITGA3
|
Applications/Dilutions
Application Notes |
This RNAi causes protein knockdown.
|
Packaging, Storage & Formulations
Storage |
Store at -20C. Avoid freeze-thaw cycles.
|
Notes
This product is produced by and distributed for Abnova, a company based in Taiwan.
Alternate Names for Integrin alpha 3/CD49c RNAi
- antigen identified by monoclonal J143
- CD49 antigen-like family member C
- CD49c antigen
- CD49c
- FLJ34631
- FLJ34704
- FRP-2
- Galactoprotein B3
- GAP-B3
- GAPB3CD49C
- Integrin alpha 3
- integrin alpha-3
- integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)
- ITGA3
- MSK18
- VCA-2
- very late activation protein 3 receptor, alpha-3 subunit
- VL3A
- VLA-3 subunit alpha
- VLA3a
Background
Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene. The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo. Chimera RNAi has many advantages over the conventional siRNAs. First, it has been demonstrated to have reliable knock-down for over 10,000 human genes. Because the human genome is composed of an intricate, genetic network, chimera RNAis unique design has successfully obviated the off-target effects including microRNA-based influence. Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected. Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.